

Europe Cancer Biomarkers Market Size Expected to Reach USD 9.56 billion with Growing CAGR of 11.0% by 2030

Data Bridge Market Research analyses that the cancer biomarkers market which was USD 4.15 billion in 2022, would rocket up to USD 9.56 billion by 2030,

PUNE, MAHARASHTRA, INDIA,
December 27, 2022 /

[EINPresswire.com/ -- Europe Cancer Biomarkers market](https://www.databridgemarketresearch.com/ -- Europe Cancer Biomarkers market) analysis report

covers detailed value chain analysis of the market. The value chain analysis helps to analyse major upstream raw

materials, major equipment, manufacturing process, and downstream customer analysis and major distributor analysis are mentioned in the report along with all the drivers and restraints for the market. It presents a comparative detailed analysis of the all regional and player segments, offering readers a better knowledge of the areas in which they can place their existing resources and gauging the priority of a particular region in order to boost their standing in the market.


Data Bridge Market Research analyses that the cancer biomarkers market which was USD 4.15 billion in 2022, would rocket up to USD 9.56 billion by 2030, and is expected to undergo a CAGR of 11.0% during the forecast period 2023 to 2030.

Grab Sample Report with Complete Graphs, Charts and Figures @

<https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-cancer-biomarkers-market>

Recent Development

- In February 2022, Abbott Laboratories released Lingo, a consumer bio wearable that can track important body signals and help consumers better understand and improve their overall health. It could allow biohackers to use a continuous stream of data rather than periodic finger-prick



tests, urine samples, and breath readings.

- In February 2022, OncoDNA, a genomic and prognostic business, released the OncoDEEP kit. The kit provides a complete workflow solution that allows laboratories with NGS capabilities to undertake thorough biomarker testing, perform advanced data analysis, and assist oncologists in providing the most effective and customized cancer treatments for their patients.

Market Outline: -

Biomarkers (also known as signature molecule or molecular marker) are basically utilized to check how the body responds to a treatment of any condition or disease and assist in examining the organ functions and other health conditions. These play a vital role in the imaging technology so that they can provide clear imaging of oncology tumours and other problems.

According to the Globocan 2020 estimates, there were 467,965 new cases of cancer in France, with 185,621 deaths. According to the Foundation de France, cancer affects over 350,000 people each year and kills close to 150,000, accounting for roughly one-third of all deaths. Increased efforts in R&D are being made to invent novel cancer therapeutics and diagnostics due to the high prevalence of cancer. Thus, cancer biomarkers are discovered to play a critical role in risk assessment and early diagnosis.

Some of the major players operating in the cancer biomarkers market are:

F. Hoffmann-La Roche Ltd. (Switzerland)

Thermo Fisher Scientific Inc. (U.S.)

Abbott (U.S.)

QIAGEN (Germany)

PerkinElmer, Inc. (U.S.)

Merck KGaA (Germany)

Bio-Rad Laboratories, Inc. (U.S.)

Enzo Biochem, Inc. (U.S.)

Charles River Laboratories (U.S.)

Eurofins Scientific (Luxembourg)

Agilent Technologies, Inc. (U.S.)

Bruker (U.S.)

Siemens (U.S.)

Epigenomics AG (Germany)

General Electric (U.S.)

Access Full 350 Pages PDF Report @

<https://www.databridgemarketresearch.com/reports/europe-cancer-biomarkers-market>

Europe Cancer Biomarkers Market Dynamics

Drivers

Rising R&D activities

In November 2019, Hitachi and the Centre Léon Bérard cancer centre in France promoted R&D aimed at improving the efficiency of cancer diagnosis and treatment by establishing the Hitachi Lyon Lab. The research also includes the identification of biomarkers in the context of resistance using genomic data, which may allow for the prediction of responses and prognoses following radiation treatment. As a result, the high cancer burden and increased R&D activities are driving the market growth.

Rise in lung cancer

Lung cancer is caused by the uncontrolled proliferation of abnormal cells in one or both lungs. Although it can affect people who have never smoked, smokers are at the greatest risk of developing lung cancer. The duration and number of cigarettes smoked by the patient increase the risk of lung cancer. Other risk factors include second-hand smoke, asbestos, certain metals, some organic chemicals, radiation, air pollution, and diesel exhaust in the workplace or in the environment. With the rise in cancer cases, millions of people worldwide are becoming infected with COVID-19. Since the focus of healthcare facilities has shifted to COVID-19, cancer patients' treatment and cancer biomarker-related clinical trials have been paused for a period of time.

Opportunities

Rising cancer cases

According to Globocan 2020 estimates, there were 457,960 new cancer cases in the United Kingdom, with prostate, breast, lung, colon, and skin cancer being the most common types of cancer detected. According to the same estimates, Italy had 415,269 new cancer cases and approximately 174,759 deaths. As a result of the rising number of cancer cases, the cancer biomarkers market in Europe is expected to grow significantly during the forecast period.

Restraints/Challenges

High treatment costs

The obstacles such as high investment requirements, high treatment costs, and expensive capital expenditure on equipment are expected to stymie market expansion, as are technical challenges with sample collection and a lack of suitable reimbursement.

Table of Content:

Section 01: Executive Summary

Section 02: Scope of The Report

Section 03: Research Methodology

Section 04: Introduction

Section 05: Market Landscape

Section 06: Market Sizing

Section 07: Five Forces Analysis

Section 08: Market Segmentation by Product

Section 09: Market Segmentation by Application

Section 10: Customer Landscape

Section 11: Market Segmentation by End-User

Section 12: Regional Landscape

Section 13: Decision Framework

Section 14: Drivers and Challenges

Section 15: Market Trends

Section 16: Competitive Landscape

Section 17: Company Profiles

Section 18: Appendix

For More Insights Get Detailed TOC @

<https://www.databridgemarketresearch.com/toc/?dbmr=europe-cancer-biomarkers-market>

[Europe Cancer Biomarkers Market Scope](#)

The cancer biomarkers market is segmented on the basis of type, product, service, disease, indication, application, profiling technologies. The growth amongst these segments will help you

analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

Consumables

Services

Software

Growth Hormone Therapy

Profiling Technologies

OMICS

Imaging Technology

Immunoassays

Cytogenetics

Bioinformatics

Service

Sample Preparation

Assay Development

Biomarkers

Testing

Type

Safety Biomarkers

Efficacy Biomarkers

Predictive Biomarkers

Surrogate Biomarkers

Prognostic Biomarkers

Pharmacodynamics Biomarkers

Validation Biomarkers

Protein Biomarkers

Genetic Biomarkers

Application

Diagnostics

Drug Discovery and Development

Personalized Medicine

Disease Risk Assessment
Others

Disease Indication

Cancer

Solid biopsy

Liquid Biopsy

Infectious Diseases

Immune Disorders

Neurological Disorders

Cardiovascular Disorders

Prostate Cancer

Breast Cancer

Lung Cancer

Colorectal Cancer

Cervical Cancer

Other Disease Indications

Frequently asked questions:

What is the Forecast Market Value for Europe Cancer Biomarkers Market?

What is the Growth Rate of the Europe Cancer Biomarkers Market?

Which are the Major Market Drivers for Europe Cancer Biomarkers Market?

What are the Major Companies Operating in the Europe Cancer Biomarkers Market?

Which Countries Data is covered in the Europe Cancer Biomarkers Market?

Browse Trending Reports:

Europe Offsite Sterilisation Service Market – Industry Trends and Forecast to 2029

<https://www.databridgemarketresearch.com/reports/europe-offsite-sterilization-services-market>

Europe Optical Imaging Market – Industry Trends and Forecast to 2028

<https://www.databridgemarketresearch.com/reports/europe-optical-imaging-market>

Europe Molecular Diagnostics Market – Industry Trends and Forecast to 2028

<https://www.databridgemarketresearch.com/reports/europe-molecular-diagnostics-market>

Europe Molecular Diagnostic Controls Market – Industry Trends and Forecast to 2028

<https://www.databridgemarketresearch.com/reports/europe-molecular-diagnostic-controls-market>

Europe Whole Exome Sequencing Market – Industry Trends and Forecast to 2029

<https://www.databridgemarketresearch.com/reports/europe-whole-exome-sequencing-market>

Europe Health Tourism Market – Industry Trends and Forecast to 2029

<https://www.databridgemarketresearch.com/reports/europe-health-tourism-market>

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Sopan Gedam

Data Bridge Market Research

+ +1 888-387-2818

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/608345575>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.